Punit Dhillon

Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor

Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma

Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug

Punit Dhillon Recent News

Benzinga Cannabis Hour Recap: Skye Bioscience CEO Discusses How Cannabinoids May Treat Glaucoma

Cannabinoid receptors distributed within the body are part of the endocannabinoid system that largely affects processes such as mood, memory, pain-sensation, and appetite, to name a few.

Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.